Alkermes plc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $36.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-25
- Alkermes plc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $36.43M, a 34.32% decline from fiscal 2024.
- Alkermes plc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $55.47M, a 5.27% increase from fiscal 2023.
- Alkermes plc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was $52.69M.
- Alkermes plc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$3.89M, a 135.48% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 9 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $36.43M 10-K · filed 2026-02-25 | ||
| 2024-12-31 | $55.47M 10-K · filed 2026-02-25 | ||
| 2023-12-31 | $52.69M 10-K · filed 2026-02-25 | ||
| 2022-12-31 | -$3.89M 10-K · filed 2025-02-12 | -$20.91M 10-K · filed 2023-02-16 | |
| 2021-12-31 | $10.97M 10-K · filed 2024-02-21 | -$4.91M 10-K · filed 2022-02-16 | |
| 2020-12-31 | -$12.07M 10-K · filed 2023-02-16 | ||
| 2019-12-31 | -$24.63M 10-K · filed 2022-02-16 | ||
| 2018-12-31 | -$15.87M 10-K · filed 2021-02-11 | ||
| 2017-12-31 | -$17.91M 10-K · filed 2020-02-13 | ||
| 2016-12-31 | -$26.80M 10-K · filed 2019-02-15 | ||
| 2015-12-31 | -$28.00M 10-K · filed 2018-02-16 | ||
| 2014-12-31 | -$1.75M 10-K · filed 2017-02-17 | ||
| 2013-12-31 | $675.00K 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |